ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Intellia Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -203.39% of over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -363.15 MM
- NET SALES(HY) At USD 38.06 MM has Grown at 29.03%
- NET PROFIT(HY) Higher at USD -187.56 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 65.22%, its profits have risen by 16.7%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 65.22% in the last 1 year, much higher than market (S&P 500) returns of 22.24%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Intellia Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Intellia Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Intellia Therapeutics, Inc.
61.96%
-0.35
99.07%
S&P 500
20.78%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.14%
EBIT Growth (5y)
-203.39%
EBIT to Interest (avg)
-398.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.18
EV to EBIT
-2.39
EV to EBITDA
-2.48
EV to Capital Employed
4.19
EV to Sales
15.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-175.20%
ROE (Latest)
-60.37%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -363.15 MM
NET SALES(HY)
At USD 38.06 MM has Grown at 29.03%
NET PROFIT(HY)
Higher at USD -187.56 MM
RAW MATERIAL COST(Y)
Fallen by -0.46% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 6.73 times
EPS(Q)
Highest at USD -0.81
-3What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 825.87 MM
DEBT-EQUITY RATIO
(HY)
Highest at -47.59 %
NET SALES(Q)
At USD 15.05 MM has Fallen at -11.05%
Here's what is working for Intellia Therapeutics, Inc.
Operating Cash Flow
Highest at USD -363.15 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -187.56 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.81
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 6.73 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -0.46% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Intellia Therapeutics, Inc.
Net Sales
At USD 15.05 MM has Fallen at -11.05%
over average net sales of the previous four periods of USD 16.92 MMMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 825.87 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -47.59 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
